This PDF is the current document as it appeared on Public Inspection on 03/12/2014 at 08:45 am.
By Notice dated November 2, 2013, and published in the Federal Register on November 19, 2013, 78 FR 69447, GE Healthcare, 3350 North Ridge Avenue, Arlington Heights, Illinois 60004-1412, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Cocaine (9041), a basic class of controlled substance listed in schedule II.
The company plans to import small quantities of ioflupane, in the form of three separate analogues of Cocaine, that will be used for the support and manufacture of DaTSCAN (ioflupane I-123) injections for distribution as a radioactive diagnostic imaging agent utilized in the diagnosis of Parkinson's disease.
No comments or objections have been received. The DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of GE Healthcare to import the basic class of controlled substance is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA has investigated GE Healthcare to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed.Start Signature
Dated: February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 2014-05480 Filed 3-12-14; 8:45 am]
BILLING CODE 4410-09-P